New Pyridobenothiazolone Derivatives Display Nanomolar Pan‐Serotype Anti‐Dengue Virus Activity
ChemMedChem · 2025
DOI: 10.1002/cmdc.202500163 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Tommaso Felicetti und 13 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Scienze Farmaceutiche, Università degli Studi di Perugia, Via Del Liceo, 1-06123, Perugia, Italy. Hauptthemen laut MEDLINE: Dengue Virus, Antiviral Agents, Benzothiazoles, Thiazoles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Singapore National Medical Research Council, NextGenerationEU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases.
Abstract (Originalsprache)
Dengue virus (DENV) serotypes 1–4 are mosquito‐borne flaviviruses that are responsible for significant morbidity and mortality worldwide, particularly in tropical and subtropical regions. Although two vaccines have been approved, their unbalanced efficacy across serotypes poses potential risks for specific populations. There are currently no approved antiviral treatments for DENV, resulting in a clear medical need, especially in endemic countries. Herein, a medicinal chemistry optimization of the pyridobenzothiazolone (PBTZ) derivative 2 is conducted, which results in the synthesis of a new series of PBTZ analogues. Compounds 15 and 19 exhibit nanomolar EC 50 values against all four DENV serotypes. While new PBTZ analogues do not inhibit DENV polymerase as the first series of PBTZ analogues do, they display anti‐DENV activity across all time points during time‐of‐addition assays and demonstrate the capacity to influence the infectivity of newly produced virions without affecting viral RNA synthesis. Compound 19 exhibits an EC 50 of 50 nM against DENV‐2 and a selectivity index of >2074, representing the most potent PBTZ analogue reported to date, with a significant improvement of over 30‐fold compared to the initial hit 2 . In vitro pharmacokinetic studies conducted on compound 19 disclose a promising profile, but with still some suboptimal values.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dipartimento di Scienze Farmaceutiche, Università degli Studi di Perugia, Via Del Liceo, 1-06123, Perugia, Italy.
- Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, 169857, Singapore.
- Dipartimento di Farmacia, Università degli Studi di Salerno, Via Giovanni Paolo II, 132, 84084, Fisciano, Italy.
- Institute for Biomedicine and Glycomics, Griffith University, Queensland, 4222, Australia.
ORCID-Profile: Tommaso Felicetti, Kitti Wing Ki Chan, Ciro Milite, Pietro Campiglia, Satoru Watanabe, Stefano Sabatini, Serena Massari, Oriana Tabarrini, Gianluca Sbardella, Subhash G Vasudevan, Giuseppe Manfroni
Förderung
- Singapore National Medical Research Council
- NextGenerationEU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases
Zitieren
APA
Felicetti, T., Gwee, C. P., Chan, K. W. K., Pepe, G., Milite, C., Campiglia, P., Watanabe, S., Mazlan, M. D. B. M., Sabatini, S., Massari, S., Tabarrini, O., Sbardella, G., Vasudevan, S. G., & Manfroni, G. (2025). New Pyridobenothiazolone Derivatives Display Nanomolar Pan‐Serotype Anti‐Dengue Virus Activity. ChemMedChem. https://doi.org/10.1002/cmdc.202500163
Vancouver
Felicetti T, Gwee CP, Chan KWK, Pepe G, Milite C, Campiglia P, et al. New Pyridobenothiazolone Derivatives Display Nanomolar Pan‐Serotype Anti‐Dengue Virus Activity. ChemMedChem. 2025. doi:10.1002/cmdc.202500163
BibTeX
@article{Felicetti2025,
author = {Felicetti, Tommaso and Gwee, Chin Piaw and Chan, Kitti Wing Ki and Pepe, Giacomo and Milite, Ciro and Campiglia, Pietro and Watanabe, Satoru and Mazlan, Muhammad Danial Bin Mohd and Sabatini, Stefano and Massari, Serena and Tabarrini, Oriana and Sbardella, Gianluca and Vasudevan, Subhash G and Manfroni, Giuseppe},
title = {New Pyridobenothiazolone Derivatives Display Nanomolar Pan‐Serotype Anti‐Dengue Virus Activity},
journal = {ChemMedChem},
year = {2025},
doi = {10.1002/cmdc.202500163}
}
EUVIMED